Moderate-severe Plaque Psoriasis Research Articles

Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study.

Ixekizumab, a monoclonal antibody against interleukin-17A, demonstrated effectiveness in the treatment of psoriasis in a Chinese real-world study that was consistent with previous randomized controlled trials. Here, we report further analyses from this study to explore the effectiveness of ixekizumab for treating patients with psoriasis and the involvement of special body areas (scalp, nail, joint, palmoplantar, or genital areas). A multicenter, prospective, observational, single-arm, post-marketing surveillance study was conducted in patients aged ≥ 18years with moderate-to-severe plaque psoriasis and prescribed with ixekizumab in 26 Chinese hospitals. Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores were compared between patients with versus without psoriasis in special body areas in the overall study population and across subgroups by body area. In total, 612 patients were included. At baseline, most patients (93.6%) had psoriasis involvement in at least one special body area. Overall, patients with psoriasis in special body areas reported a worse quality of life (QoL) than those without. Patients with versus without psoriasis in special body areas achieved a comparable mean reduction from baseline in PASI score (10.9 vs. 9.2 at week2, and 16.9 vs. 14.7 at week12, respectively) and DLQI score (6.0 vs. 4.4 at week2, and 9.9 vs. 7.5 at week12, respectively); a similar proportion of patients also achieved PASI50 at week2, and PASI75 and PASI90 at week12, and a DLQI (0/1) at weeks2 and 12. Several significantly different results were reported between subgroups, the majority of which favored patients with special body area involvement. Most patients had psoriasis involvement in a special body area which was associated with worse QoL. Ixekizumab is similarly effective in reducing disease severity and improving QoL in patients with plaque psoriasis across different special body areas.

Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).

Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real-life data remain scarce. BrIDGE was an observational, prospective, single-cohort, multicentre study that recruited patients with moderate-to severe plaque psoriasis in Greece. The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short-term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12-16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab. Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, 'worst case' and 'best case' scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables. Based on the 'as observed data', 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12-16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12-16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%. Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate-to-severe psoriasis patients.

Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data

ObjectiveUstekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti-tumour necrosis factor a drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinumab in moderate-severe plaque psoriasis refractory to 2 anti-tumour necrosis factor a drugs. MethodRetrospective descriptive study from January 2010 to March 2019. The study included patients with moderate-severe plaque psoriasis previously treated with at least 2 anti-tumour necrosis factor a biologic drugs. The effectiveness endpoints were Psoriasis Area and Severity Index 90 and 75 response rates at weeks 24, 48, 72, and 96. Safety was assessed using adverse effects and treatment withdrawal. ResultsA total of 36 patients were included (men, 61%). Ustekinumab was used after treatment with 2 anti-tumour necrosis factor a drugs in 88.9% of patients. The biologic drugs most frequently administered prior to ustekinumab were infliximab (94.4%) and etanercept (91.7%). It was observed that at least 66.7% of patients reached Psoriasis Area and Severity Index 90 at weeks 24, 48, 72, and 96. Adverse effects were recorded in 6 patients. There were no treatment withdrawals. ConclusionsUstekinumab showed real long-term effectiveness and safety in moderate-severe plaque psoriasis with inadequate response to 2 previous anti-tumour necrosis factor a drugs.

Line-field confocal optical coherence tomography: New insights for psoriasis treatment monitoring.

Line-field confocal optical coherence tomography (LC-OCT) is a new, valid means for a rapid and non-invasive invivo examination of the epidermis and upper dermis, allowing digital interpretation and measurement of high-resolution images on a cellular level. Given these properties, it may represent a valid tool for monitoring psoriasis during treatment, allowing a new method to set a precise objective severity of the disease. We aimed to investigate the potentialities of LC-OCT in the non-invasive monitoring of microscopical changes associated with moderate-severe plaque psoriasis (PP) during the treatment with the most common biological drugs. We performed LC-OCT imaging of PP lesions from 17 patients before and after 8 weeks of treatment. The clinical severity of the single lesions was evaluated using a lesion score (LS), designed considering three parameters: erythema, desquamation and infiltration. LC-OCT images were segmented by artificial intelligence and evaluated based on three microscopic criteria: the thickness of the stratum corneum, the thickness of the living epidermis and the undulation of the dermo-epidermal junction. Line-field confocal optical coherence tomography digital analysis allowed recognition and quantification of the three microscopic criteria, showing a reduction of all these during the follow-up. Furthermore, a high correlation between change in LS and the thickness of the stratum corneum and the thickness of the living epidermis was found. Line-field confocal optical coherence tomography can non-invasively monitor the response of PP to different treatments. Morphometric changes occurring in the psoriatic lesion during the 8-week treatment period were identified by invivo LC-OCT and measured by using artificial intelligence. Although future studies are required, based on these preliminary results, LC-OCT may represent a valid potential tool for precise monitoring of therapeutic response.

43928 Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Up to 5 Years of Follow-up

43928 Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Up to 5 Years of Follow-up

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.

Psoriasis is a chronic systemic inflammatory disease that significatively impairs patients' quality of life. Biological treatments are highly effective and safe and have led to breakthroughs in the management of patients with moderate-to-severe psoriasis. However, therapeutic response can be unsatisfactory or lost with time, leading to discontinuation of treatment. Bimekizumab is a humanized monoclonal antibody that specifically inhibits both interleukin (IL)-17A and IL-17F. The efficacy and safety of bimekizumab in moderate-to-severe plaque psoriasis has been demonstrated in Phase 2 and Phase 3 clinical trials. Bimekizumab may offer some advantages over other biological treatments, making it especially indicated for certain patients. This narrative review aims to summarize the latest published evidence on the use of bimekizumab for the treatment of moderate-severe plaque psoriasis, focusing on patient selection and therapeutic perspectives. Bimekizumab has been shown to be more efficacious than adalimumab, secukinumab and ustekinumab in clinical trials, with high estimated probabilities of achieving complete (approximately 60%) or almost complete clearance (approximately 85%) of psoriasis at weeks 10-16, and a good safety profile. Response to bimekizumab is usually fast and maintained in the long term for both biologic-naive patients and those resistant to previous biologic treatments. The usual maintenance dose of 320 mg every 8 weeks makes bimekizumab especially convenient for non-compliant patients. Moreover, the efficacy and safety of bimekizumab have also been demonstrated in psoriasis affecting challenging-to-treat areas,psoriatic arthritis and hidradenitis suppurativa. In conclusion, dual inhibition of IL-17A and IL-17F with bimekizumab is a good therapeutic option for moderate-to-severe psoriasis.

Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis.

Biologics is used for treating moderate to severe plaque psoriasis (MSPP), which represent one of the foremost therapeutic advancements in disease of dermatology. Up to now, the relative efficacy and safety across approved andinvestigational biologics for MSPP is still unclear. This study aimed to comparative effectiveness of various biological treatments for MSPP measured by PASI75, PASI90 and PASI100 (The ratio of patients whose Psoriasis Area and Severity Index score (PASI) decreased by ≥ 75%, 90% and 100% compared with baseline, respectively). In addition, random models were used together with a Bayesian method to compare direct and indirect Adverse Events (AEs) of biologics with placebo, to make probabilistic statements and predictions on their AEs. The analytic data set was made up of summarized data from 54 trials, including 27,808 patients, with treatment of 17 biologics. Three mathematic models with nonparametric placebo evaluations were established to characterize the longitudinal direction profile for the three efficacy measures as above mentioned. Our results showed significant differences among treatments. Bimekizumab, sonelokimab, and ixekizumab were found to be the most effective treatments among the biologics. The effects of covariate were further evaluated, patients' age, body weight, duration of disease and percentage of patients previously treated with a biological therapy showed impact on the efficacy. In addition, we found that ixekizumab and risankizumab displayed relatively stable as for efficacy and safety. Our findings provide valuable insights into the comparative effectiveness and safety of biologics for MSPP treatment. These results may aid in clinical decision-making and ultimately improve patient outcomes.

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study.

Genital psoriasis affects 3-33% of patients with psoriasis during the course of the disease, usually leading to a severe reduction in the patient's quality of life. This study aims to retrospectively assess the effectiveness of interleukin (IL)-23 and IL-17 inhibitors in a real-life population affected by moderate-to-severe plaque psoriasis with genital involvement coming from our dermatology department. A total of 86 patients with a diagnosis of moderate-tosevere plaque psoriasis with severe genital involvement were enrolled. Patient characteristics, psoriasis area and severity index (PASI), and static physician global assessment of genitalia (sPGAG) at each visit were recorded. During the treatment, the mean PASI decreased from 12.8 to 0.63 at week 52; a PGA of 0/1 was reached by 97.40% at week 52 and by 100% of patients (37/37) at week 104. No significant differences between IL-23 and IL-17 inhibitors were observed; indeed, the bio-naïve group of patients demonstrated a superior response compared to the group of bioexperienced patients.Our findings confirmed that IL-23 and IL-17 inhibitors are safe and effective therapeutic options for the treatment of genital psoriasis.

33270 Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up

RZB is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits IL-23 by binding to its p19 subunit. In the ongoing LIMMitless open-label extension study (NCT03047395), patients initially randomized to receive RZB 150 mg for the treatment of moderate-to-severe plaque psoriasis in 5 double-blind phase 3 trials (UltIMMa-1/NCT02684370, UltIMMa-2/NCT02684357, SustaIMM/NCT03000075, NCT03255382, IMMvent/NCT02694523) were eligible to continue open-label RZB 150 mg every 12 weeks. This interim analysis evaluated efficacy through 232 weeks of continuous RZB treatment and safety up to the data cutoff (March 26, 2021); data beyond 4.5 years will be presented.

Efficacy and Safety of Tripterygium Wilfordii Glycoside Tablets Combined with Acitretin Capsules in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

Objective To probe into the clinical efficacy of tripterygium wilfordii glycoside (TWGs) tablets combined with acitretin capsules in the treatment of patients with moderate to severe plaque psoriasis (MSPP). Methods Thirty-six patients with MSPP were collected and divided into three groups, namely, group A (n = 12, TWG tablets + acitretin capsules), group B (n = 12, compound glycyrrhizin capsules + acitretin capsules), and group C (n = 12, acitretin capsules). The general data of the patients was recorded. In addition, a comparison was made before treatment, 4 weeks and 8 weeks after treatment in terms of the clinical efficacy, liver function indicators (alanine aminotransferase (ALT), aspartate transaminase (AST), and creatinine), psoriasis area, and severity index (PASI) scores. The incidence of adverse reactions after treatment and the recurrence rate during two months of follow-up was statistically analyzed. Results The therapeutic effect of group A was superior to the other two groups, with obviously more satisfactory results of serum parameters, clinical efficacy and PASI score, and incidence of adverse reactions. Conclusions TWGs combined with acitretin had better therapeutic effects and higher safety in the treatment of MSPP.

Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

ABSTRACT Background Real-world data on guselkumab, especially at times >6 months, are limited. Research design and methods We performed a longitudinal, retrospective analysis on 307 patients with moderate–severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months. Main outcome measures PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. Results At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naïve to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale. Conclusions Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate–severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.

Biyolojik Tedavi Kullanan Psöriyazis Hastalarına COVID-19'un Etkileri: İki Merkezli Retrospektif Çalışma

Objective: The aim of our study is to evaluate the status of continuation of treatment of our patients who received biologic treatment during the pandemic and how they were affected by coronavirus disease-2019 (COVID-19). Material and Methods: The clinical processes of patients with moderate-severe plaque psoriasis who were treated with biologics between March 2020 and February 2021 were evaluated. Results: Thirty-three (21.2%) of our 156 psoriasis patients who received biologic therapy stopped treatment at the beginning of the pandemic. Fourteen of the 123 patients who were continuing the treatment were positive for COVID-19. One of the 33 psoriasis patients who stopped biologic treatment was positive for COVID-19. There was no statistical difference between those who continued with biologic treatment and those who did not in the rates of positivity for COVID19 after contact with a COVID-19 positive person, and frequency of severe symptoms (p=0.607, p=1.00, respectively). In terms of the difference between the mean of Psoriasis Area Severity Index (PASI) scores at the onset of the pandemic and the mean of PASI scores at the 12th month, there was no statistical difference between those who were positive for COVID-19 and those who did not (p=0.782). Conclusion: We have observed that the treatment with biologic agents in psoriasis patients does not increase the COVID-19 transmission risk, does not cause severe disease, and does not increase the hospitalization rate and mortality rate.

Monitorización farmacocinética de adalimumab como marcador precoz de fallo secundario en los pacientes con psoriasis en placa moderada-grave

Objectiveto analyze the relationship between infra-therapeutic serum concentrations (SC) of adalimumab (ADA) and secondary failure to treatment in patients with moderate-severe plaque psoriasis. Patients and methodretrospective observational study. Inclusion criteria: adult patients diagnosed with moderate–severe plaque psoriasis under treatment with ADA in whom a pharmacokinetic monitoring had been performed. Variables: demographic, related to the pathology (psoriasis area severity index (PASI) ≥ 5 non-responder), related to treatment (time under treatment and dosage schedule) and related to monitoring (ADA SC (μg/ml) and anti-adalimumab antibodies (AAA; UA/ml)).The association between the results of the pharmacokinetic monitoring and the effectiveness of treatment was evaluated through the relationship between the infra-therapeutic SC (< 3.5 μg/ml) and the appearance of secondary failure, as well as the time elapsed. Results25 patients (7 women) were included, with 49 (95%CI 44,54) years, being 36% (9/25) non-responders. The patients were treated with ADA during 3.6 (95%CI 26, 4.7) years, 32% (8/25) with the dosage schedule reflected in the summary of product characteristics, 40% (10/25) with optimizations and 28% (7 / 25) with intensification. 34 monitoring of ADA Sc were performed (1.4 monitoring/patient), with a median of 3.8 (IQR 9.2) μg/ml; and 12 AAA monitoring (1.1 monitoring/patient), 6 of them being positive. In 57% (4/7) of patients with infra-therapeutic ADA SC, secondary treatment failures were evidenced 3.4 (IQR 1.5) months after the pharmacokinetic monitoring was performed. ConclusionsADA pharmacokinetic monitoring is a tool to support clinical decisions that allows knowing and predicting the clinical response in patients with moderate-severe plaque psoriasis.

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.

EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included. With a follow-up visit at 6months after enrolment, each patient had at least 12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life, and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients.

Implications of narrowband ultraviolet B treatment on psoriasis severity and serum levels of angiopoietin-2: A cross-sectional controlled study.

Psoriasis is a chronic inflammatory hyper proliferative skin disease. Angiogenesis play an important role in Psoriasis pathogenesis, occurring even before plaque formation. Angiopoietins play an important role in angiogenesis and hence are described as angiogenic factors. To evaluate serum levels of angiopoeitin 2 (Ang-2) following treatment with narrowband ultraviolet B (NBUVB) in patients with moderate-severe plaque psoriasis and correlate it to psoriasis area and severity index (PASI). This cross sectional study included 38 patients complaining of moderate to severe plaque psoriasis and 38 healthy controls. Psoriasis area and severity index (PASI) was determined and was correlated to serum levels of Ang-2 before and after treatment with NBUVB. PASI scores and serum values of angiopoietin 2 demonstrated a significant difference between the baseline and at the end of the 12weeks NBUVB treatment. A statistically significant positive correlation was established between psoriasis severity and Ang-2 serum levels before and after treatment. The study demonstrated a potential contribution of Ang-2 in the pathogenesis of psoriasis, as well as its usefulness as a biomarker of psoriasis severity.

25696 Impact of guselkumab on quality of life and work productivity outcomes among patients with moderate-to severe plaque psoriasis in the Corrona Psoriasis Registry

Background: Guselkumab is an IL-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis (PsO). Plaque PsO is known to impact patient-reported outcomes (PROs). Little is known about the impact of persistent guselkumab treatment on PROs among real-world patients.

PSS3 Cost-Effectiveness Analysis of Biologic Treatments for Plaque Psoriasis in Italy: Results of the Canova Study

To estimate the cost per responder of biologics for plaque psoriasis in Italy based on the CANOVA study. CANOVA was an observational (retrospective and prospective) cohort study conducted in 17 Italian dermatology clinics, including adult patients with moderate-severe plaque psoriasis, who had started a biologic treatment in a retrospective period between 24 and 6 months before enrollment. Patients were observed from the start of the most recent retrospective biologic (baseline) until a 6-month visit after enrollment. Data on resource consumption (biologic and non-biologic drugs, inpatient and outpatient care) and response ( achievement of 75%/90%/100% improvement in baseline PASI-Psoriasis Area and Severity Index) were collected at 16/24/52 weeks from baseline. Cost per responder was calculated as direct costs (retrieved from national databases) divided by number of responders. Descriptive analyses were performed on the overall sample and stratified by the currently most-frequently prescribed biologics (i.e. adalimumab originator; ixekizumab; secukinumab; ustekinumab). Among 669 eligible patients, median annualized cost was €14,699 (interquartile range: €13,785 - €15,779), with biologics being the driver of expenditure. Costs per PASI-75, PASI-90 and PASI-100 responder at 52 weeks were €20,281 (N=551; response rate: 91%), €24,662 (N=540; 75%) and €35,045 (N=564; 53%), respectively. Cost per responder (considering PASI-90) at 52 weeks varied by treatment group, with lowest values in adalimumab (€22,755; N=62) and secukinumab (€23,978; N=238) and highest values in ixekizumab (€24,743; N=63) and ustekinumab (€27,522; N=140). The lowest cost per sustained response, i.e. achievement of at least PASI-75 response both at 16 and at 52 weeks, was observed for secukinumab (€21,375; N=169; response rate: 86%). Cost-effectiveness profile of biologics was positive (because of high response) with some trends in favour of adalimumab and secukinumab. Besides patient preferences and comorbidities, cost per response is useful to guide treatment decisions.

17817 Prospective observational study to evaluate the benefits for the patient associated with the treatment of plaque psoriasis with apremilast after other systemic treatments in conditions of clinical practice in Spain (APPROPRIATE study)

The aim of this 12-month, observational, prospective, multicenter study was to assess the benefits of apremilast for the treatment of moderate-severe plaque psoriasis in routine practice in Spain. Interim analysis including 75 patients (mean age 52.7 years [SD15.6]) who started apremilast treatment 3 months before inclusion. 75 were followed for 3 months, and 41 for 6; 9 (12%) discontinued during the 6-month period, 6 of them due to adverse events (AEs). All patients had previously received at least one conventional systemic treatment and had not received biologicals. Mean (SD) Psoriasis Area Severity Index (PASI) was 8.3 (5.6), 3.5 (3.1), and 3.2 (4.6) at baseline, 3, and 6 months, respectively (*P * 1 and 54.2% (39/72) PBI ≥3. Pruritus intensity (VAS (SD)) decreased from 52.0 (32.6) at baseline to 28.0 (29.6, *P < .0001) and 35.4 (33.3, *P = .0048) and Dermatology Life Quality Index (DLQI [SD]) decreased from 10.6 (6.6) to 4.5 (6.2, *P < .0001) and 3.7 (5.4, *P < .0001). 45.2% (33/73) and 47.4% (18/38) of patients achieved DLQI 0/1 at months 3 and 6 respectively (***P < .0001). 25 patients (33.3%) reported AEs (1/31 [3%] was serious). The most frequent AEs were gastrointestinal alterations (14.7%). These preliminary data suggest apremilast is an effective treatment with an acceptable safety profile, providing substantial benefits for patients with moderate to severe psoriasis. *Paired t test; **McNemar test; ***Symmetry test.

Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a ‘perceived satisfaction’: a multicentric study

Objective Thanks to their specificity of action, biologic drugs often lead to complete clearance of psoriatic lesions. In order to maintain its effectiveness, biological therapies cannot be discontinued. The aim of the study was to investigate the effect of widening the administration window of four biologic drugs, thus improving the quality of life of psoriatic patients and satisfying their desire to feel free from the disease, without loss of effectiveness. Methods We performed a multicentric cohort study considering patients with moderate-severe plaque psoriasis and/or arthropathic psoriasis treated with infliximab, adalimumab, etanercept or ustekinumab. The study group included patients with stabilized psoriasis in which the administration regimen of the biologic drug was deferred. The control group included psoriatic patients treated according the product monograph. Results The percentage of relapses in case of deferred administration intervals was comparable to that of standard administration intervals. The delayed administration modality got a good psychological consensus from the patients themselves, that reported a greater ‘perceived satisfaction’. A consistent economic advantage was reported in case of prolonged administration intervals. Conclusions The administration of biologic drugs with prolonged intervals maintains the same effectiveness as standard administration and produces a ‘perceived satisfaction’ in psoriatic patients.

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)